m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00710)
Target Name M-phase inducer phosphatase 2 (CDC25B)
Synonyms
Dual specificity phosphatase Cdc25B
    Click to Show/Hide
Gene Name CDC25B
Chromosomal Location 20p13
Family MPI phosphatase family
Function
Tyrosine protein phosphatase which functions as a dosage-dependent inducer of mitotic progression. Required for G2/M phases of the cell cycle progression and abscission during cytokinesis in a ECT2-dependent manner. Directly dephosphorylates CDK1 and stimulates its kinase activity. The three isoforms seem to have a different level of activity.
    Click to Show/Hide
Gene ID 994
Uniprot ID
MPIP2_HUMAN
HGNC ID
HGNC:1726
Ensembl Gene ID
ENSG00000101224
KEGG ID
hsa:994
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
CDC25B can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Methyltransferase-like 3 (METTL3) [WRITER]
 Regulator Info 
Representative RNA-seq result indicating the expression of this target gene regulated by METTL3
Cell Line HeLa cell line Homo sapiens
Treatment: METTL3 knockdown HeLa cells
Control: HeLa cells
 GSE70061
Regulation
logFC: 2.72E+00
p-value: 5.89E-03
More Results Click to View More RNA-seq Results
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary METTL3 enhanced the m6A modification of M-phase inducer phosphatase 2 (CDC25B) mRNA, which maintained its stability and upregulated its expression, thereby activating G2/M phase of cell cycle and leading to HNSCC malignant progression.
Target Regulation Up regulation
Responsed Disease Head and neck squamous carcinoma ICD-11: 2B6E
 Disease Info 
Cell Process Cell proliferation
Cell migration
Cell invasion
In-vitro Model Tu 686 Laryngeal squamous cell carcinoma Homo sapiens CVCL_4916
Tu 212 Head and neck squamous cell carcinoma Homo sapiens CVCL_4915
SAS Tongue squamous cell carcinoma Homo sapiens CVCL_1675
HUVEC-C Normal Homo sapiens CVCL_2959
HEp-2 Endocervical adenocarcinoma Homo sapiens CVCL_1906
FaDu Hypopharyngeal squamous cell carcinoma Homo sapiens CVCL_1218
In-vivo Model Tumour xenograft models were established in nude mice bearing: SAS cells cells stably transfected with METTL3-shRNA and the corresponding control vector. The different HNSCC cells (5 × 106) were subcutaneously injected into the right axilla of nude mice (n = 6 per group).
Head and neck squamous carcinoma [ICD-11: 2B6E]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary METTL3 enhanced the m6A modification of M-phase inducer phosphatase 2 (CDC25B) mRNA, which maintained its stability and upregulated its expression, thereby activating G2/M phase of cell cycle and leading to HNSCC malignant progression.
Responsed Disease Head and neck squamous carcinoma [ICD-11: 2B6E]
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Up regulation
Cell Process Cell proliferation
Cell migration
Cell invasion
In-vitro Model Tu 686 Laryngeal squamous cell carcinoma Homo sapiens CVCL_4916
Tu 212 Head and neck squamous cell carcinoma Homo sapiens CVCL_4915
SAS Tongue squamous cell carcinoma Homo sapiens CVCL_1675
HUVEC-C Normal Homo sapiens CVCL_2959
HEp-2 Endocervical adenocarcinoma Homo sapiens CVCL_1906
FaDu Hypopharyngeal squamous cell carcinoma Homo sapiens CVCL_1218
In-vivo Model Tumour xenograft models were established in nude mice bearing: SAS cells cells stably transfected with METTL3-shRNA and the corresponding control vector. The different HNSCC cells (5 × 106) were subcutaneously injected into the right axilla of nude mice (n = 6 per group).
References
Ref 1 METTL3 modulates m6A modification of CDC25B and promotes head and neck squamous cell carcinoma malignant progression. Exp Hematol Oncol. 2022 Mar 14;11(1):14. doi: 10.1186/s40164-022-00256-3.